Bordetella pertussis pertactin antigen

DB10789ApprovedInvestigationalVaccines

Bordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .

First approval
Canada, 2001 · United States, 2002 · European Union, 2021
Also known as
Bordetella pertussis pertactin vaccine, inactivated · Pertactin · Pertactin adsorbed
Brand names
  • Adacel
  • Boostrix
  • Daptacel
  • Infanrix Hexa
  • Pentacel
  • Quadracel
  • Vaxelis

Resolves to

Compound
UNII63GD90PP8X
Clinical / RWD
RxNorm1300184

What you can answer from here — as of April 02, 2025

95Clinical trialsPhase, status and sponsor resolved per trial
Sign in
119Marketed productsAcross 10 countries and 15 labellers
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of Bordetella pertussis pertactin antigen, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In